APA (7th ed.) Citation

N, S., W, Q., JS, C., C, M., PA, S., M, T., . . . N, B. (2022). Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates. Journal of pharmaceutical sciences, 111(5), 1486. https://doi.org/10.1016/j.xphs.2021.10.027

Chicago Style (17th ed.) Citation

N, Salamat-Miller, Qu W, Chadwick JS, McPherson C, Salinas PA, Turner M, Wang D, and Barton N. "Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates." Journal of Pharmaceutical Sciences 111, no. 5 (2022): 1486. https://doi.org/10.1016/j.xphs.2021.10.027.

MLA (9th ed.) Citation

N, Salamat-Miller, et al. "Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates." Journal of Pharmaceutical Sciences, vol. 111, no. 5, 2022, p. 1486, https://doi.org/10.1016/j.xphs.2021.10.027.